Detalhe da pesquisa
1.
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Hematol Oncol
; 42(1): e3216, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37772620
2.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artigo
Inglês
| MEDLINE | ID: mdl-33651883
3.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33739461
4.
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Future Oncol
; 15(19): 2227-2239, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31137964
5.
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience.
Hematol Oncol
; 38(1): 111-113, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31852014
6.
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.
Cancers (Basel)
; 15(5)2023 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36900295
7.
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?
Clin Lymphoma Myeloma Leuk
; 22(6): 356-361, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34969641
8.
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
Ther Adv Hematol
; 13: 20406207221127550, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36246422
9.
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.
Cancers (Basel)
; 13(8)2021 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33921415
10.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Blood Adv
; 5(24): 5490-5500, 2021 12 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34525181
11.
Duvelisib for the treatment of chronic lymphocytic leukemia.
Expert Opin Pharmacother
; 21(11): 1299-1309, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32292084
12.
Ibrutinib for the treatment of chronic lymphocytic leukemia.
Expert Rev Hematol
; 12(5): 273-284, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30916599
13.
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.
Hemasphere
; 7(5): e880, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37153871
14.
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
Leuk Lymphoma
; 63(8): 1985-1988, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35343363
15.
The management of chronic lymphoproliferative disorders at the time of SARS-Covid2 pandemic: weathering the storm.
Leuk Lymphoma
; 61(13): 3278-3279, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32700978
16.
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).
Leukemia
; 34(9): 2531-2532, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32753689